Esya's mission is the early, precise and cost-effectivedetection of neurodegenerative diseases using breakthrough cell-scanningtechnology well before the disease symptoms manifest physically. Today,Alzheimer's disease (AD) affects one in six of us and, according to theAlzheimer's Society, costs society £34.7 billion a year. AD is a costly problemwith no single diagnostic and no personalized treatment plan, and by the timeit is diagnosed the disease is already very advanced. Our diagnostic assay,Esya AD360, harnesses intracellular DNA nanoprobes to capture and profile ADlysosomal signatures which combines to transcriptomic changes and plasmapathological markers thereby enabling early, accurate and reliable diseasedetection.

Lysosomes are sub-cellular organelles responsible for the clearanceof aggregate-prone proteins. Dysfunctional lysosomes are common factors ingenetic and sporadic forms AD. The major goal of this project is to develop amultiparametric biomarker panel to monitor lysosomal ionic homeostasis,measuring plasma pathological biomarkers and a developing RNA panel thatrepresents the cellular transcriptomic changes.

Our patented technology operates in the nexus of biochemistry,neuroscience, and AI. We aim to provide a 360 perspective with a first-in-classdiagnostic to chemically profile AD, monitor and track disease progression anddevelop a lysosomally-targeted pipeline for novel therapeutics. Throughexpedited diagnoses and reduced costs and stressors, AD patients, theirfamilies and carers will see a significant improvement in their quality oflife.